* Please note that the following agenda timings are Eastern Standard Time.
8:30 am
Join us for a coffee morning to meet your peers ahead of the conference
8:45 am Chair’s Opening Remarks
TGF-β in Immuno-Oncology: The Story So Far
9:00 am The Role of TGF-β in the Tumor Ecosystem & Immunotherapy
9:30 am An Overview of the TGF-β IO Market
10:00 am
Morning Networking Break
Synopsis
Meet and connect with your peers in this dedicated networking session.
Preclinical Track
Moving Beyond the Challenges of Preclinical Tumor Models
10:30 am Preclinical Models Reveal Heterogeneous Responses to TGF-β Antagonism & Highlight Potential Sites of Off-Tumor Toxicities
11:00 am Inhibition of Integrin αvβ8 in Combination with Low Dose Radiation Induces Antitumor Effect in Advanced Immune Checkpoint Blockade Refractory Tumor Model
11:30 am Therapeutic Inhibition of TGF-β Mediated Immune Suppression
Clinical Track
The Latest Clinical Advances
10:30 am BCA101, A Novel Dual-Action Antibody Combining the Precision Targeting of EGFR with the Immunomodulating Power of TGF-β
11:00 am Clinical Update on TST005
11:30 am Bintrafusp Afla: What, Why & How?
12:00 pm Networking Lunch
Novel Insights into Mechanisms of TGF-β Regulators
1:00 pm Impact of Dual TGF-β/PD-L1 Therapeutic Blockade on CD8 T Cell Phenotypes
1:30 pm How to Design Targetable Forms of TGF-β
2:00 pm Roundtable Discussion
Exploring the Clinical Landscape
1:00 pm Understanding the TGF-β Landscape
1:30 pm Optimizing Clinical Studies to Evaluate Safety & Tolerability
2:00 pm Roundtable Discussion
2:30 pm
Afternoon Networking Break & Poster Exhibition
Synopsis
This scientific poster exhibition is an opportunity to present your latest data and innovation with your peers.
Elevating Innovative Approaches to Regulation of TGF-β
3:00 pm Expression of a TGF-β Inhibitor from an Oncolytic Vaccinia Virus
3:30 pm Targeting Autotaxin – A Novel Approach to Interrupt TGF-β-Mediated Pathology
4:00 pm Chair’s Closing Remarks
4:10 pm End of Day One
